Supreme Court Ruling Boosts Bayer in Roundup Cases

A U.S. Supreme Court decision led to an 18% rise in Bayer shares by limiting Roundup cancer lawsuits. The ruling dismisses current claims and bars future failure-to-warn claims, benefiting science, farmers, and industries that rely on regulatory clarity. Bayer expects litigation containment after years of legal battles.

The U.S. Supreme Court has issued a ruling that significantly reduces the number of Roundup cancer lawsuits. This decision caused Bayer shares to jump by 18%, representing a victory for the company.

The ruling is expected to dismiss current warning-based claims and prevent future failure-to-warn lawsuits, according to Bayer's statement on Thursday. The company hailed the decision as favorable for science, farmers, and industries dependent on regulatory clarity for innovation.

Bayer anticipates that this legal development will substantially curb ongoing Roundup litigation, marking a potential endpoint in nearly a decade-long series of legal challenges.